Autumn 2019 â€˘ Promotional Supplement
High-resolution Mapping in Patients with Persistent ` the ` Atrial Fibrillation: A Case-based Review of PENTARAYâ„˘ Catheter Marius Andronache, Clermont Ferrand Centre, France Nikola Drca, Karolinska Institute, Sweden Graziana Viola, San Francesco Hospital, Italy The publication of this case series was supported by Biosense Webster 108490-190227 EMEA
Lifelong Learning for Cardiovascular Professionals
Cases This publication reflects the independent opinions of Drs Andronache, Drca and Viola. Unless expressly stated, the materials do not represent the opinion of, and have not been reviewed for accuracy or completeness by the Johnson & Johnson Medical Device Companies. This publication is not intended for distribution outside of the EMEA region.
High-resolution Mapping in Patients with Persistent Atrial Fibrillation: A Case-based Review of the PENTARAY™ Catheter Marius Andronache, 1 Nikola Drca 2 and Graziana Viola 3 1. Clermont Ferrand Centre, France; 2. Karolinska Institute, Sweden; 3. San Francesco Hospital, Italy
Abstract Ablation of AF through electrical isolation of the pulmonary veins is a well-established procedure and a cornerstone in the ablation of AF, with a variety of techniques and ablation strategies now available. However, high numbers of patients are returning to hospital following ablation procedures such as pulmonary vein isolation (PVI). Scar tissue is found present in many of these patients, in particular those with persistent AF and even those with paroxysmal AF. This scarring is associated with poor outcomes after PVI. Cardiac mapping is necessary to locate triggers and substrate so that an ablation strategy can be optimised. The PENTARAY™ Catheter (Biosense Webster) is a technology that offers the physician more information regarding the status of the tissue compared with standard ablation catheters, which can lead to improved outcomes. This article discusses the importance of substrate mapping in persistent AF and presents case studies illustrating the utility of the PENTARAY™ Catheter.
Keywords Atrial fibrillation, catheter ablation, PENTARAY™ Catheter, pulmonary vein isolation, substrate mapping Disclosure: Nikola Drca has has received consultancy fees from Biosense Webster. Marius Andronache and Graziana Viola have no conflicts of interest to declare. Citation: Arrhythmia & Electrophysiology Review 2019;8(3 Suppl 1). DOI: https://doi.org/10.15420/aer.2019.8.3.S1 Correspondence: Nikola Drca, Department of Cardiology, Karolinska Institute, Karolinska University Hospital, Stockholm SE-141 86, Sweden. E: email@example.com Support: The publication of this case series was supported by Biosense Webster. Katrina Mountfort and Bettina Vine of Medical Media Communications (Scientific) Ltd provided medical writing and editing support to the authors, funded by Biosense Webster.
AF is the most common sustained cardiac arrhythmia in clinical practice. It is associated with increased risk of stroke and heart failure and is a significant global health challenge.1 Catheter ablation procedures, which isolate the pulmonary veins (PV) from the left atrium (LA) and prevent AF initiation, are effective and safe treatment options. They have emerged as the preferred rhythm control strategy for symptomatic paroxysmal AF that is refractory or intolerant to at least one antiarrhythmic medication.2,3 Catheter ablation of AF is the most common technique and is now the most commonly performed catheter ablation procedure. PV isolation (PVI) has become the standard of care in paroxysmal AF therapy.4 This procedure is associated with a high success rate (>70%) in paroxysmal AF, but with persistent AF the success rate remains low at around 50–60%.1 Success rates exceeding 70% are possible with better techniques, workflow and technological options, with some studies reporting up to 90% success rates.5–8 Despite advances and growing experience in percutaneous catheter ablation for AF, long-term outcomes for persistent AF are inferior to
Access at: www.AERjournal.com
those for paroxysmal AF.4,9–12 High numbers of patients with persistent AF return to hospital and additional substrate ablation is frequently performed.13 Scar tissue is present in many of these patients, particularly in those with persistent AF but is also seen in those with paroxysmal AF. This scarring is associated with poor outcomes after PVI.14–16 This has led to the development of ablation strategies to eliminate low-voltage regions caused by scarring within the LA. This article aims to discuss the challenges of atrial scarring in patients with persistent AF and substrate mapping strategies for optimising the ablation of atrial scarring.
The Challenges of Atrial Scarring Understanding the AF substrate is essential to improving outcomes in catheter ablation of patients with persistent AF and can enable individualised treatment approaches.17,18 A growing body of evidence indicates that pre-existing or iatrogenic atrial fibrosis, or scarring, plays a role in the maintenance of AF.19 Animal studies have shown that propagation of fibrillation waves is promoted by endocardial bundles in acute AF and by epicardial bundles in persistent AF.20 Atrial fibre bundle rearrangement results in more perpendicular orientation of epicardial
© RADCLIFFE CARDIOLOGY 2019
High-resolution Mapping of AF to endocardial bundles, causing endo-to-epicardial dissociation of electrical activity and the formation of a 3D AF substrate.20 However, while the definition of ventricular scar is well established, this approach has been more challenging in the atrium because of the structure of the atrial wall and the great difficulty of detecting atrial fibrosis with existing imaging techniques.21 Atrial fibrosis can separate cardiomyocyte bundles, which can hinder electrical coupling and slow electrical conduction.22 The presence of scarring in the LA in patients with AF has therefore been associated with an abnormal electroanatomic substrate causing lower regional voltage, increased proportion of low voltage, slowed conduction, and an increased proportion of complex signals compared with controls.16 In a study of 700 consecutive patients undergoing PVI for the first time, pre-existing LA scarring was a strong independent predictor of procedural failure and was associated with a lower ejection fraction (EF), larger LA size, and increased inflammatory markers, with patients experiencing LA scarring having a significantly higher AF recurrence (57%) compared with patients without scarring (19%; p=0.003).14 In a multicentre, prospective, observational cohort study of patients diagnosed with paroxysmal and persistent AF undergoing their first catheter ablation with PVI, atrial tissue fibrosis estimated by delayed enhancement MRI (n=272) was independently associated with the risk of recurrent arrhythmia.15 A promising new strategy for ablation of AF is atrial scar-based catheter ablation to modify low-voltage regions that may indicate scarring and/or zones of non-uniform anisotropic conduction within the LA and convert them into electrically silent regions.18,23,24 In a study that compared the 2-year outcomes in patients with paroxysmal AF and severe LA scarring identified by 3D mapping who were undergoing PVI only or PVI plus scar homogenisation, the latter group had significantly better long-term outcomes than PVI alone. While single procedures had a low success rate, ablation of non-PV triggers during repeat procedures resulted in significantly better outcomes.25
Methods of Analysing the Extent and Severity of Scarring Pre-procedure
Table 1: Summary of Studies Investigating Multielectrode Mapping Using the PENTARAY™ Catheter Reference
Anter at al. 201535
Comparison of mapping resolution with 3.5 mm electrode tip linear catheters (THERMOCOOL™ Catheter) and PENTARAY™ Catheter in 10 patients with structurally normal atria and 20 patients with scar-related atrial arrhythmias
In patients with scar-related atrial arrhythmias, the total area of bipolar voltage <0.5 mV measured using PENTARAY™ Catheter was smaller than that measured using the THERMOCOOL™ Catheter (14.7 versus 20.4 cm2; p=0.02). The mean bipolar voltage amplitude in this area was significantly higher with the PENTARAY™ Catheter (0.28 and 0.17 mV; p=0.01). Additionally, 54.4% of all low-voltage data points recorded with the PENTARAY™ Catheter had distinct electrograms that allowed annotation of local activation time versus 21.4% with the PENTARAY™ Catheter (p=0.01).
Seitz et al. 201727
Prospective study. AF was sequentially mapped in patients admitted for AF ablation (n=105) with a PENTARAY™ Catheter and compared with a validation set.
After ablation of 17 ± 10% of the left atrial surface over a follow-up of 18 months, the recurrence rate of atrial arrhythmia was 15% in the PENTARAY™ Catheter group (after 1.4 ± 0.5 procedures per patient) versus 41% in the validation set (1.5 ± 0.5 procedures per patient). Arrhythmia freesurvival was 85% versus 59%; p<0.001). Radiofrequency times (49 ± 21 min versus 85 ± 34.5 min; p=0.001) and procedure times (168 ± 42 min versus 230 ± 67 min; p<0.0001) were shorter in the PENTARAY™ Catheter group compared with the validation set.
Bun et al. 201837
Procedures with PENTARAY™ Catheter (n=17) were compared to historical cases with conventional technique (n=17)
A mean of 449 ± 520 points within 14 ± 6 min were acquired per atrial tachycardia in the PENTARAY™ Catheter group (n=17) versus 42 ± 18 points (p<0.0001) within 33 ± 25 min (p=0.04) in the conventional group (n=17). All 25 atrial tachycardia isthmuses were easily identified and ablated in the PENTARAY™ Catheter group (100%) versus 87% in the conventional group (p=0.056). The ablation time was shorter in the PENTARAY™ Catheter group (760 ± 540 versus 1,347 ± 962 s; p=0.037). Procedure and fluoroscopy times were not significantly different between the two groups. Recurrence occurred in fewer patients in the PENTARAY™ Catheter group (0% versus 23.5%; p=0.033) during a mean follow-up of nearly 1 year.
A number of studies have concluded that substrate mapping is a useful tool to guide personalised AF substrate modification in patients undergoing AF ablation (Table 1).6,18,26–28 In a study that compared electrophysiological abnormalities in 80 patients with AF (30 paroxysmal AF, 22 persistent AF, and 28 long-standing AF), and 20 matched controls, high-density 3D electroanatomic mapping showed that the low-voltage index increased gradually from control to paroxysmal AF, persistent AF and long-standing AF.29 In a singlecentre randomised study, individually tailored substrate modification guided by voltage mapping was associated with a significantly higher arrhythmia-free survival rate compared with a conventional approach applying linear ablation according to AF type.30 A recent meta-analysis concluded that voltage-guided substrate modification by targeting low-voltage areas in addition to PVI is more effective and safer than conventional ablation approaches, although the authors cautioned that more randomised studies are needed.31
persistent AF. A Class IIB recommendation was also given to creation of linear ablation lines (in the absence of documented macro-reentrant flutter), complex fractionated atrial electrograms ablation, rotor ablation, extensive posterior wall ablation or targeting of autonomic ganglionic plexi in persistent AF. Ablation of non-PV triggers, if found, was given a Class IIA recommendation.4
The 2017 Heart Rhythm Society expert consensus document assigned a Class IIB recommendation to mapping and ablation of areas of abnormal myocardial tissue identified with voltage mapping or MRI as an initial or repeat ablation strategy for persistent or longstanding
The most commonly used cardiac mapping approach is isochronal or activation mapping, which is based on non-fluoroscopic visualisation of mapping catheters and a partial model of the wavefront excitation sequence created by the manipulation of a mapping catheter.32
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
Cases The most widely available electroanatomical mapping systems are the CARTO™ 3 System (Biosense Webster), RHYTHMIA HDx™ (Boston Scientific) and EnsiteNavX® (Medical).33,34
approach was used, radiofrequency (RF) times and procedure times were shorter.27
Case Studies However, these approaches may be challenging. Cardiac mapping can be difficult if scarring is present because of lack of capture in these areas of low voltage.35 The difficulties arise from a poor understanding of events such as collision waves and anisotropy in the low-voltage and fragmented areas and how to modify these abnormal electrical areas in order to ‘normalise’ them. Another challenge is that lowvoltage areas in AF are greater than in sinus rhythm and difficult to correlate with MRI findings. Scar maps obtained by electroanatomic mapping or MRI have emerged as a useful tool to guide personalised AF substrate modification in patients undergoing AF ablation, and are supported by a growing body of evidence.24 Before the availability of the PENTARAY™ Catheter (Biosense Webster), it was much more challenging and sometimes almost impossible to map arrhythmias in atria that were scarred. The large tip in an ablation catheter made it impossible to see any signals in scarred tissue. Large parts of the atria appeared to be completely silent, and it was not possible to map the arrhythmia. Localised re-entries in scarred tissue were impossible to see. The use of a PENTARAY™ Catheter offers an important addition to the voltage map, helping clinicians understand the arrhythmias and understand them in a better way. One of the challenges associated with use of the catheter is that it is time consuming to produce advanced voltage maps, even with PENTARAY™ Catheter.
The PENTARAY ™ Catheter as a Tool for Substrate Mapping in Clinical Practice The standard catheter for mapping the LA is a linear catheter with a 3.5 mm distal electrode separated by 2 mm from a proximal 2 mm electrode, resulting in a centre-to-centre interelectrode spacing of 4.75 mm.35 In recent years, a number of multi-electrode contact-based catheters (PENTARAY™ Catheter) and the Duo-Decapolar® catheter (Livewire®, 2-2-2 mm spacing, St Jude Medical) have been introduced into clinical practice. T The PENTARAY ™ Catheter, used in conjunction with the CARTO™ 3 System system, allows the sampling of multiple points of cardiac mapping data. The device contains 20 electrodes, spaced along five branches that radiate from the deflectable tip. The catheter’s contact with the endocardium surface is atraumatic and provides a high-density map from its 1 mm electrodes, covering an area of 6.25 cm2.28 Compared with point-by-point voltage maps, PENTARAY™ Catheter maps have been shown to have significant advantages, such as higher mapping resolution that can identify heterogeneity within the area of low voltage, localising channels of surviving bundles; the ability to record higher bipolar voltage amplitude with shorter electrogram duration; and pacing with capture at lower output because of increased electric density.35,36 The utility of the PENTARAY™ Catheter has been demonstrated in a number of case reports and studies of patients with AF (Table 1).27,28,35,37,38 In a recent prospective study (Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation [SUBSTRATE HD]; NCT02093949), AF was sequentially mapped in both atria of 105 patients admitted for AF ablation, using the PENTARAY™ Catheter. Compared with a validation set in which a conventional ablation
The following three sections describe case studies illustrating the utility of the PENTARAY™ Catheter.
Case Study 1 The patient was a 68-year-old man with hypertension and ischaemic heart disease. He had experienced AF since 2007 – initially paroxysmal, but during the last 6 months persistent. Previously failed antiarrhythmic treatment included disopyramide, sotalol and dronedarone. His BMI was 25 kg/m2. An echocardiogram showed EF 55%, end-diastolic diameter 53 mm and parasternal long axis 43 mm. He had undergone PVI in 2015 and received a redo procedure in August 2018. The electrophysiological study was performed under sedation with midazolam and alfentanil and propofol were given just for the electroconversion. The patient was electroconverted from AF to sinus rhythm after the transseptal puncture when the long sheaths were in place and the PENTARAY™ Catheter was placed in the LA. The anatomical and electroanatomical mapping (EAM) of the LA was performed with PENTARAY™ 2-6-2 mm Catheter (D-curve) during coronary sinus (CS)-paced rhythm. The CS catheter was used as a reference, and the window of interest was set to +5–10 ms from the CS reference to avoid mapping pacing artefacts and +15 ms from the beginning of the QRS complex to avoid mapping signals from the ventricle. The continuous point acquisition was done with multielectrode mapping using the PENTARAY™ Catheter with the help of the CARTO™ 3 System V6 CONFIDENSE™ Module (Biosense Webster). Tissue proximity indicator (TPI) was used to determine the electrode proximity to cardiac tissue. The continuous mapping filters in the CONFIDENSE™ Module were set to the following: TPI on, cycle length (CL) range ± 5 ms of the paced rhythm, local activation time (LAT) stability 4 ms, position stability 4 mm, density 1 mm, and force above minimum threshold. To collect continuous points with the ablation catheter, the pattern matching filter was turned on for CS-paced rhythm to avoid collecting points during extrasystole. Wavefront annotation was used. The bipolar voltage threshold was set to 0.2–0.5 mV for the diseased area and the colour fill threshold was set to 6 mm. The anatomical map and the EAM were created simultaneously by placing the PENTARAY™ Catheter deep into the left superior pulmonary vein (LSPV) and retracting it slowly while rotating the catheter and the long introducer clockwise and making sure to have initial contact with the posterior part of the left PV. Slow movement was made around the PV ostium and the antrum, carefully looking for potential gaps in previous ablation lines. Pauses were made in the slow movement to collect points. It is important to ensure there is contact and to collect points around the PV ostium and the antrum around the circumference of all veins. In areas where low-voltage signals (<0.5 mV) were found, dense points were collected and it was made certain that they were reproducible. The colour fill threshold was set to 6 mm and the LA was fully covered. When creating the anatomy of the LA with PENTARAY™ Catheter, the atrial wall is not pushed as much as when the anatomy is created with the Lasso catheter, because of the PENTARAY™ Catheter’s five soft radiating spines. This means the anatomy more closely resembles the true anatomy of the atrium.
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
High-resolution Mapping of AF In this case, the left PVs had a common trunk that had been isolated since the prior procedure in 2015. There was PV re-conduction to the right superior pulmonary vein (RSPV) and right inferior pulmonary vein (RIPV), and there was a patchy scar area in the roof (Figures 1 and 2). Both the voltage map and conventional signals in the PENTARAY™ Catheter clearly showed the reconnection to the right PV. Only PVI was done in this case and the small patchy scar area was not targeted. Ablation was done with point by point with the THERMOCOOL SMARTTOUCH® Catheter (Biosense Webster), using CARTO VISITAG™ for tagging ablation points. A tag index of 550 was used for the anterior wall and 400 for the posterior wall. Interlesion distance was <6 mm. A new voltage map was made after the PVI. This showed low voltage (<0.2 mV) distal to the ablation line around the right PVs (Figure 3). When checking for PV isolation after the ablation, it is important to rotate the PENTARAY™ Catheter around the PV ostium and check for PV potentials and to avoid using just the voltage map. Furthermore it is very important to check for signals between the veins.
Figure 1: Case 1. Posterosuperior View
Small low voltage area in the roof of the left atrium and signals in PENTARAY™ Catheter showing pulmonary vein potentials in the right pulmonary veins.
Figure 2: Case 1. Modified Right Anterior Oblique View
The CONFIDENSE™ Module uses impedance differences between blood pool and tissue (the TPI) to determine that the PENTARAY™ Catheter has contact with the atrial wall. There will be oedema in the tissue immediately after ablation, which makes it more difficult for the CONFIDENSE™ Module to determine if there is contact. Sometimes the clinician may have problems collecting continuous points with the PENTARAY™ Catheter using the CONFIDENSE™ Module around ablation lines straight after the ablation. If this problem is encountered, reset the TPI after ablation. The voltage map will be used to discuss the further ablation strategy with the patient if they are not helped by PVI alone. In the case of a redo, a modified roof line in the shape of a V can be drawn between the right PV and the left common trunk to address the low-voltage area in the roof.
PENTARAY™ Catheter showing pulmonary vein potentials in the right pulmonary veins.
Figure 3: Case 1. Modified Right Anterior Oblique View
Without the high density map there would have been no additional information about fibrosis and dispersion areas. Moreover, the PENTARAY™ Catheter allowed fast mapping without any additional difficulties on entry to the pulmonary vein (especially the right inferior). In addition, checking the vein isolation using the PENTARAY™ Catheter is faster and more reproducible compared with the Lasso catheter. These factors are less important in paroxysmal AF, but in persistent AF time and information are crucial.
Case Study 2 The patient was a 47-year-old woman with lone persistent AF (longlasting; >6 months). The catheters used were Deflectable 10 electrodes F curve, PENTARAY™ Catheter F curve 2-6-2 mm and THERMOCOOL SMARTTOUCH® Catheter F curve, with a single transseptal puncture. After the transseptal puncture, a counter-clockwise torsion was made through the sheath in order to reach the RSPV with the PENTARAY™ Catheter. The PENTARAY™ Catheter was pushed deep inside the vein until no signal was recorded. Then, in order to define the ostium of the vein, the catheter was pulled back with light curve and slowly turned around the vein. Respiratory gating was done at this point. The inferior pulmonary vein was reached by pulling out the catheter from the RSPV, by maintaining a counter clockwise torsion and then
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
PENTARAY™ Catheter showing isolation of the right superior pulmonary vein.
by bending it. The ostium of the RIPV was identified by performing the same manoeuvres described for RSPV. The entire mapping phase was performed in AF with the aid of CARTO™ 3 System V6 CONFIDENSE™ Module (number of points acquired: 2,716; bipolar voltage map 0.2–0.5 mV; with filters and settings in the CONFIDENSE™ Module set to the following: TPI on, LAT stability off, position stability 4–6 mm; Figure 4). Mapping time was 18 minutes. Low-voltage areas were delineated based on a bipolar voltage of <0.5 mV during AF (determined as the maximum bipolar voltage of two consecutive AF beats), according to the current literature.6,29,39–41 In
Cases Figure 4: Case 2. Bipolar Voltage Map in AF
Figure 7: Case 2. Electrograms and Bipolar Voltage Map after Ablation, Right Pulmonary Vein
Anterior view (left panel) and posterior view (right panel).
Figure 5: Case 2. Electrograms in the Superior Pulmonary Vein
Figure 8: Case 2. Electrograms and Bipolar Voltage Map after Ablation, Right Pulmonary Vein
Figure 6: Case 2. Electrograms in the Superior Pulmonary Vein
AI when oesophageal injury suspected). Sinus rhythm was restored during RF application in the roof of the RSPV. Right and left veins were successfully isolated at the end of the procedure. In order to check isolation, a new bipolar map was produced using the PENTARAY™ Catheter using higher voltage values (1mv-0,2), focusing on the ostium of each PV. This proved the absence of gaps around the lesion lines (Figures 7 and 8). In addition, by selecting the spline in contact with the tissue, the exit block was verified by stimulating within the line of the lesion. The entrance block was confirmed by stimulating the proximal CS electrodes. The PENTARAY™ Catheter creates an anatomy of the LA that is closer to the true anatomy. This makes it easier and safer to plan and perform the ablation lines. A multipolar catheter with smaller electrodes with closer interelectrode spacing facilitates detection of gaps, facilitating a safer and more effective PVI.
this case, few areas of bipolar <0.5 mV were detected, and the high signal resolution of the PENTARAY™ Catheter allowed the identification of spatio-temporal dispersion areas.42,43 Most of the dispersion regions were found around the RSPV (Figures 5 and 6). By adding bipolar mapping with dispersion signals information, the adopted ablation strategy was PVI only without any additional areas or line. A point-by-point ablation (interlesion distance 6 mm, 35 W) was started from the RSPV. CARTO VISITAG Module with Ablation Index (AI) was 500 in the anterior wall and 380 in the posterior wall (300
The PENTARAY™ Catheter is not better just for scar-related AF but also in all types of AF compared with a standard circular (Lasso) catheter. An electrophysiologist who doubts substrate-based ablation and wants to perform a standard PVI could also benefit from using the PENTARAY™ Catheter instead of a Lasso catheter. Substrate-based ablation has a Class IIB recommendation while PVI has a Class IA. PENTARAY™ Catheter creates a better anatomy and is better for mapping gaps. Therefore it will still confer advantages even if the operator chooses only to perform a PVI.
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
High-resolution Mapping of AF Figure 9: Case 3. Fractionation 1
The left panel shows the superior LA view and fragmented signals with dispersion area on PENTARAY™ Catheter placed on the anterosuperior (high LA septum). HD colouring map in AF. The right panel shows UniVu and LA CT scan, 10 poles catheter in the right atrial appendage with more organised signals. HD = high definition; LA = left atrium.
Case Study 3 The patient was a 65-year-old woman with lone persistent AF since 2012. She had no structural heart disease, normal EF and a dilated LA (28 cm2). Treatment with flecainide failed and was replaced by amiodarone. This was followed by two electrical cardioversions, the last one in January 2018 with fast recurrence. Ablation was performed in July 2018. Catheters used were: deflectable 10 electrodes F curve in CS, PENTARAY™ Catheter F curve 2-6-2 mm, THERMOCOOL SMARTTOUCH® Catheter F curve, with a single transseptal puncture with general anaesthesia. After the transseptal puncture, the guidewire was pushed into the LSPV, the sheath advanced in the vein or close (note: ensure this is not moved into the LAA) and the PENTARAY™ Catheter introduced deep inside the vein until no signal was recorded. CS CL was 170 ms with fragmented signals on the proximal side, while the LAA CL was 160 ms. In order to define the ostium of the vein, the catheter was pulled back with a clockwise rotation to define the posterior border of the vein and counter clockwise rotation for the anterior part of the vein. When the catheter jumped into the LAA, the points were annotated as ostium or ridge. This manoeuvre was repeated for the anterior part of the LSPV and left inferior pulmonary vein (LIPV), and for the inter-venous space. When the PENTARAY™ Catheter jumped from the LSPV to the LIPV (pullback and clockwise rotation), there was rotation around the veins for a complete anatomy. Real anatomy was merged on the table with the CT scan (using CARTO-Merge) after left PV and LAA reconstruction, with variable transparency after reconstruction. Delimitation of the ridge between LAA and anterior part of the left PVs is crucial for isolation of the left PVs. The same importance is given for accurate mapping and ablation of the posterior side of the LAA when signals are very fragmented. After ridge definition, careful reconstruction of the LAA anatomy with PENTARAY™ Catheter, anterior and posterior side, and annotation of the fast and/or fragmented signals (target for ablation after PVI) was performed. The PENTARAY™ Catheter was rotated clockwise on the posterior wall with RSPV catheterisation. This was followed by the same manoeuvres as the left side for ostium delimitation, then a clockwise rotation for the septal side of the RSPV and anterior side of LA, with manual annotation of FS and gradient area (ablation target after PVI). It was pulled back slowly, with counterclockwise rotation for RIPV catheterisation and rotation to complete anatomy.
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
Figure 10: Case 3. Fractionation 2
LA with anteroposterior view with fragmented and low-voltage area. PENTARAY™ Catheter 1–2 up to 5–6 no signals (in the isolated right superior pulmonary vein) and PENTARAY™ Catheter 13–14 up to 19–20 on the left septum, close to the anterior side of the right superior pulmonary vein. The coronary sinus catheter was placed into the right atrium, and not into the coronary sinus. LA = left atrium.
To obtain the LA anatomy, it is very important to map the inferior side in front of the CS. We found very fragmented signals (annotation) with advanced sheath and the PENTARAY™ Catheter curved into the inferior direction and moved from the mitral annulus to the inferior part of the RIPV. Careful mapping of the mitral isthmus (normal voltage, so no ablation) is required. It is important to avoid ablation, especially in this area, if there is no FS and normal voltage, and not to induce a slow conduction to induce a perimitral flutter – this is difficult to ablate, especially to achieve a blocked line. The voltage map was performed with the PENTARAY™ Catheter at the same time as LA and PV reconstruction. TPI was always used, with filters and settings in the CONFIDENSE™ Module as follows: TPI on; CL range ± 5 ms; position stability 4 mm; and density 1 mm. Bipolar voltage threshold was set to 0.2–0.5 mV for diseased areas and the colour fill threshold was set to 5–6 mm. PVI was carried out with the SmartTouch SF contact force catheter F curve, point-by-point ablation with an ablation index of 450 on anterior part and 350 posterior part (oesophageal temperature monitoring); 40 W anterior part, 25–30 W left posterior (oesophageal temperature monitoring and RF stopped if temperature increased by 1°C), 30 W right posterior. To check PVI, check that no signals are recorded inside the PVs, and check again in sinus rhythm with exit block by pacing. LA mapping time was 10 minutes
Cases and total RF ablation time for PVI was 12 minutes. There were short RF applications (12–15 seconds/RF application with 10–20 g contact force) in order to reach the targeted ablation index. There was no modification of LAA CL after PVI. LA voltage map with high-definition colouring (3,129 points) was performed, with ablation of four areas on fragmented and low-voltage areas – septum anterior to the LAA (Figures 9 and 10), inferior LA, especially below the RIPV in front of the proximal CS, posterior between inferiors PVs, and posterior to the mitral isthmus with AF organisation into this latter area (220 ms). However, after 2 minutes there was further AF, although CL was slower (190–200 ms, variable), and there were still multiple sources for the AF. Ablation time for the four zones was 13 minutes RF (35–40 W septum, 30 W posterior [under oesophageal temperature monitoring] and 35 W inferior LA). The surface area of the LA for the four zones was 36 cm2 (13% of total LA area) and LA volume was 200 ml. A voltage right atrium map with high-definition colouring (974 points) was performed after LA ablation without low-voltage areas and longer CL (245 ms), showing there were no criteria for ablation. This was the same for the epicardial coronary sinus (230 ms). The sinus rhythm was obtained by electrical cardioversion. The procedure duration was 110 minutes and fluoroscopy time 45 seconds (0 after transseptal puncture). The PENTARAY™ Catheter was very useful to precisely quantify the surface of the low-voltage area and target inside the rapid
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016;50:e1–88. https://doi.org/10.1093/ejcts/ezw313; PMID: 27663299. 2. Nyong J, Amit G, Adler AJ, et al. Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. Cochrane Database Syst Rev 2016;CD012088. https://doi. org/10.1002/14651858.CD012088.pub2; PMID: 27871122. 3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071–104. https://doi.org/10.1161/ CIR.0000000000000040; PMID: 24682348. 4. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythm 2017;33:369–409. https://doi. org/10.1016/j.joa.2017.08.001; PMID: 29021841. 5. Taghji P, El Haddad, M, Knecht S, et al. A new approach for PV isolation in paroxysmal atrial fibrillation: ‘CLOSE’ protocol. Europace 2016;18:i184. https://doi.org/10.1093/europace/18. suppl_1.i184. 6. Jadidi AS, Lehrmann H, Keyl C, et al. Ablation of persistent atrial fibrillation targeting low-voltage areas with selective activation characteristics. Circ Arrhythm Electrophysiol 2016;9: e002962. https://doi.org/10.1161/CIRCEP.115.002962; PMID: 26966286. 7. Ciconte G, Ottaviano L, de Asmundis C, et al. Pulmonary vein isolation as index procedure for persistent atrial fibrillation: One-year clinical outcome after ablation using the secondgeneration cryoballoon. Heart Rhythm 2015;12:60–6. https://doi. org/10.1016/j.hrthm.2014.09.063; PMID: 25281891. 8. Natale A, Reddy VY, Monir G, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol 2014;64:647–56. https://doi.org/10.1016/j.jacc.2014.04.072; PMID: 25125294. 9. Tilz RR, Rillig A, Thum AM, et al. Catheter ablation of longstanding persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol 2012;60:1921–9. https://doi.org/10.1016/j.jacc.2012.04.060; PMID: 23062545. 10. Chen HS, Wen JM, Wu SN, et al. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst Rev 2012;CD007101. https://doi.org/10.1002/14651858. CD007101.pub2; PMID: 22513945. 11. Tzou WS, Marchlinski FE, Zado ES, et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:237–42. https://doi.org/10.1161/ CIRCEP.109.923771; PMID: 20335557. 12. Steinberg JS, Palekar R, Sichrovsky T, et al. Very long-term outcome after initially successful catheter ablation of
and fragmented signals in order to modify the LA substrate in this case of persistent AF.
Summary and Concluding Remarks Catheter ablation for the treatment of persistent AF is associated with suboptimal outcomes, largely because of the presence of scar tissue. AF recurrence is frequently reported, and patients often undergo repeat ablations after conventional PVI procedures. Substrate-based modification via targeting areas of scarring areas of the LA has therefore emerged as a promising therapeutic strategy to maximise long-term freedom from AF. In order to optimise accuracy and reproducibility of scar maps, there is a need for standardised protocols and uniform cutoffs for scar detection. As illustrated by the case studies, the PENTARAY™ mapping Catheter offers high spatiotemporal resolution, and ablations performed using the PENTARAY™ Catheter have been associated with shorter procedure times and fewer recurrences of AF. While the PENTARAY™ Catheter has proven useful in terms of finding abnormal areas, there remains at present no tool to facilitate our understanding of the mechanism of low-voltage areas and the optimal methods of treatment of these areas. It is hoped that the CARTOFinder will help us to improve our knowledge of persistent AF. In summary, while larger studies are needed, clinical evidence to date suggests that the use of the PENTARAY™ Catheter may facilitate successful ablation of scar-related AF.
atrial fibrillation, Heart Rhythm 2014;11:771–6. https://doi. org/10.1016/j.hrthm.2014.02.003; PMID: 24508206. 13. Darby AE, Recurrent atrial fibrillation after catheter ablation: considerations for repeat ablation and strategies to optimize success. J Atr Fibrillation 2016;9:1427. https://doi.org/10.4022/ jafib.1427; PMID: 27909521. 14. Verma A, Wazni OM, Marrouche NF, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation:. J Am Coll Cardiol 2005;45:285–92. https://doi. org/10.1016/j.jacc.2004.10.035; PMID: 15653029. 15. Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 2014;311:498–506. https://doi.org/10.1001/jama.2014.3; PMID: 24496537. 16. Teh AW, Kistler PM, Lee G, et al. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. J Cardiovasc Electrophysiol 2012;23:232–8. https://doi.org/ 10.1111/j.1540-8167.2011.02178.x; PMID: 21955090. 17. Kottkamp H, Berg J, Bender R, et al. Box Isolation of Fibrotic Areas (BIFA): a patient-tailored substrate modification approach for ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2016;27:22–30. https://doi.org/10.1111/jce.12870; PMID:26511713. 18. Rolf S, Kircher S, Arya A, et al. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:825–33. https://doi.org/10.1161/CIRCEP.113.001251; PMID: 25151631. 19. Heijman J, Algalarrondo V, Voigt N, et al. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res 2016;109:467–79. https://doi.org/10.1093/cvr/cvv275; PMID: 26705366. 20. Maesen B, Zeemering S, Afonso C, et al. Rearrangement of atrial bundle architecture and consequent changes in anisotropy of conduction constitute the 3-dimensional substrate for atrial fibrillation. Circ Arrhythm Electrophysiol 2013;6:967–75. https://doi.org/10.1161/CIRCEP.113.000050; PMID: 23969531. 21. Kapa S, Desjardins B, Callans DJ, et al. Contact electroanatomic mapping derived voltage criteria for characterizing left atrial scar in patients undergoing ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2014;25:1044–52. https://doi.org/10.1111/jce.12452; PMID: 24832482. 22. Kawara T, Derksen R, de Groot JR, et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 2001;104:3069–75. https://doi.org/10.1161/ hc5001.100833; PMID: 11748102. 23. Nery PB, Thornhill R, Nair GM, et al. Scar-based catheter ablation for persistent atrial fibrillation. Curr Opin Cardiol 2017;32:1-9. https://doi.org/10.1097/HCO.0000000000000349; PMID: 27875475.
24. Saini A, Huizar JF, Tan A, et al. Scar homogenization in atrial fibrillation ablation: evolution and practice. J Atr Fibrillation 2017;10:1645. https://doi.org/10.4022/jafib.1645; PMID: 29250241. 25. Mohanty S, Mohanty P, Di Biase L, et al. Long-term followup of patients with paroxysmal atrial fibrillation and severe left atrial scarring: comparison between pulmonary vein antrum isolation only or pulmonary vein isolation combined with either scar homogenization or trigger ablation. Europace 2017;19:1790–7. https://doi.org/10.1093/europace/euw338; PMID: 28039211. 26. Santangeli P, Marchlinski FE, Techniques for the provocation, localization, and ablation of non-pulmonary vein triggers for atrial fibrillation. Heart Rhythm 2017;14:1087–96. https://doi. org/10.1016/j.hrthm.2017.02.030; PMID: 28259694. 27. Seitz J, Bars C, Theodore G, et al. AF ablation guided by spatiotemporal electrogram dispersion without pulmonary vein isolation: a wholly patient-tailored approach. J Am Coll Cardiol 2017;69:303–21. https://doi.org/10.1016/j. jacc.2016.10.065; PMID: 28104073. 28. Mastrine L, Greenberg YJ, Yang, F. Utilization of the PentaRay NAV catheter during atrial fibrillation ablations. EP Lab Digest 2014;14. Available at: www.eplabdigest.com/articles/ Utilization-PentaRay-NAV-Catheter-During-Atrial-FibrillationAblations (accessed 24 May 2019). 29. Lin Y, Yang B, Garcia FC, et al. Comparison of left atrial electrophysiologic abnormalities during sinus rhythm in patients with different type of atrial fibrillation. J Interv Card Electrophysiol 2014;39:57–67. https://doi.org/10.1007/s10840013-9838-y; PMID: 24113851. 30. Kircher S, Arya A, Altmann D, et al. Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study. Europace 2017. https://doi.org/10.1093/europace/eux310; PMID: 29177475; epub ahead of press. 31. Blandino A, Bianchi F, Grossi S, et al. Left atrial substrate modification targeting low-voltage areas for catheter ablation of atrial fibrillation: a systematic review and metaanalysis. Pacing Clin Electrophysiol 2017;40:199–212. https://doi. org/10.1111/pace.13015; PMID: 28054377. 32. Barbhayla CR, Kumar S, Michaud GF. Mapping atrial fibrillation: 2015 update. J Atr Fibrillation 2015;8:1227. https://doi.org/ 10.4022/jafib.1227; PMID: 27957220. 33. Nedios S, Sommer P, Bollmann A, Hindricks G. Advanced mapping systems to guide atrial fibrillation ablation: electrical information that matters. J Atr Fibrillation 2016;8:1337. https:// doi.org/10.4022/jafib.1337; PMID: 27909489. 34. Khaykin Y, Oosthuizen R, Zarnett L, et al. CARTO-guided vs. NavX-guided pulmonary vein antrum isolation and pulmonary vein antrum isolation performed without 3-D mapping: effect of the 3-D mapping system on procedure duration and fluoroscopy time. J Interv Card Electrophysiol 2011;30:233–40. https://doi.org/10.1007/s10840-010-9538-9; PMID: 21253840. 35. Anter E, Tschabrunn CM, Josephson ME. High-resolution
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
High-resolution Mapping of AF
mapping of scar-related atrial arrhythmias using smaller electrodes with closer interelectrode spacing. Circ Arrhythm Electrophysiol 2015;8:537–45. https://doi.org/10.1161/ CIRCEP.114.002737; PMID: 25792508. 36. Tschabrunn CM, Roujol S, Dorman NC, et al. High-resolution mapping of ventricular scar: comparison between single and multi-electrode catheters. Circ Arrhythm Electrophysiol 2016;9: e003841. https://doi.org/10.1161/CIRCEP.115.003841; PMID: 27307518. 37. Bun SS, Delassi T, Latcu DG, et al. A comparison between multipolar mapping and conventional mapping of atrial tachycardias in the context of atrial fibrillation ablation. Arch Cardiovasc Dis 2018;111:33–40. https://doi.org/10.1016/j. acvd.2017.04.005; PMID: 28927960. 38. Pinto Teixeira P, Silva Cunha P, Delgado AS, et al. PentaRay
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
catheter in persistent atrial fibrillation ablation. Rev Port Cardiol 2016;35:121–3 [in Portuguese]. https://doi.org/10.1016/j. repc.2015.09.014; PMID: 26847911. 39. Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119:1758–67. https://doi.org/10.1161/CIRCULATIONAHA.108.811877; PMID: 19307477. 40. Jadidi AS, Cochet H, Shah AJ, et al. Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging and high-density mapping. J Am Coll Cardiol 2013;62:802–12. https://doi.org/10.1016/j.jacc.2013.03.081; PMID: 23727084.
41. Squara F, Frankel DS, Schaller R, et al. Voltage mapping for delineating inexcitable dense scar in patients undergoing atrial fibrillation ablation: a new end point for enhancing pulmonary vein isolation. Heart Rhythm 2014;11:1904–11. https://doi.org/10.1016/j. hrthm.2014.07.027; PMID: 25064249. 42. Wang XH, Li Z, Mao JL, He B. A novel individualized substrate modification approach for the treatment of long-standing persistent atrial fibrillation: preliminary results. Int J Cardiol 2014;175:162–8. https://doi.org/10.1016/j.ijcard.2014.05.022; PMID: 24874911. 43. Yamaguchi T, Tsuchiya T, Nakahara S, et al. Efficacy of left atrial voltage-based catheter ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2016;27:1055–63. https:// doi.org/10.1111/jce.13019. PMID: 27235000.
Lifelong Learning for Cardiovascular Professionals
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
Arrhythmia & Electrophysiology Review 2019;8(3 Suppl 1)